Advaxis, Inc. (NASDAQ:ADXS)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Friday. They presently have a $23.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 378.17% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald set a $19.00 price objective on Advaxis and gave the company a “buy” rating in a research note on Thursday, July 6th. BidaskClub upgraded Advaxis from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. Finally, ValuEngine upgraded Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th.

Advaxis (NASDAQ:ADXS) traded down 2.43% during trading on Friday, reaching $4.81. 1,109,532 shares of the company were exchanged. The firm’s 50 day moving average price is $6.35 and its 200-day moving average price is $7.45. The stock’s market capitalization is $194.62 million. Advaxis has a one year low of $4.77 and a one year high of $12.66.

Advaxis (NASDAQ:ADXS) last announced its quarterly earnings data on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The firm had revenue of $3.05 million during the quarter, compared to the consensus estimate of $3.43 million. On average, equities research analysts predict that Advaxis will post ($2.20) earnings per share for the current year.

WARNING: “Advaxis, Inc. (ADXS) Rating Reiterated by HC Wainwright” was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/09/15/advaxis-inc-adxs-rating-reiterated-by-hc-wainwright.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. Stevens Capital Management LP bought a new stake in shares of Advaxis during the first quarter valued at about $105,000. Voya Investment Management LLC increased its position in shares of Advaxis by 20.3% during the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 2,975 shares during the period. Cutler Capital Management LLC bought a new stake in shares of Advaxis during the second quarter valued at about $130,000. American International Group Inc. increased its position in shares of Advaxis by 7.6% during the first quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 1,459 shares during the period. Finally, Northern Capital Management LLC increased its position in shares of Advaxis by 14.6% during the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 2,650 shares during the period. Hedge funds and other institutional investors own 48.78% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.